Pharmacogenetics of antidepressant drugs: Current clinical practice and future directions

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 441-464

  Narasimhan, Sneha ^a   Lohoff, Falk W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antidepressants; anxiety disorders; bipolar disorder; depression; pharmacogenetics; treatment response

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DEBRISOQUINE; DESIPRAMINE; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; MILNACIPRAN; NORTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

5HTR1A GENE; 5HTR1B GENE; 5HTR2A GENE; 5HTR3A GENE; 5HTR3B GENE; 5HTR6 GENE; ACE GENE; ADRBETA1 GENE; ANXIETY DISORDER; BDNF GENE; BIPOLAR DISORDER; COMT GENE; CREB1 GENE; CRHR1 GENE; CRHR2 GENE; CYP450 GENE; DAT1 GENE; DRD2 GENE; DRD4 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FKBP5 GENE; GASTROINTESTINAL SYMPTOM; GENE; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC TRAIT; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GNBETA3 GENE; GRIA1 GENE; GRIA3 GENE; GRIK2 GENE; GRIK4 GENE; GRIN3A GENE; HUMAN; MAJOR DEPRESSION; MAOA GENE; MOOD DISORDER; NAUSEA; NONHUMAN; NR3C1 GENE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHARMACODYNAMICS; PHARMACOGENETICS; POSTTRAUMATIC STRESS DISORDER; PROGNOSIS; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A4 GENE; SOCIAL PHOBIA; SUICIDAL IDEATION; TPH1 GENE; TPH2 GENE; VARIABLE NUMBER OF TANDEM REPEAT;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BIOMARKERS, PHARMACOLOGICAL; DEPRESSIVE DISORDER; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC;

EID: 84857717326     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.1     Document Type: Review

References (247)

1. Rush AJ Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905-1917 (2006).
2. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch. Gen. Psychiatry 46(1), 89-99 (1989).
3. Lieberman J. History of the use of antidepressants in primary care. Primary Care Companion: J. Clin. Psychiatry 5, 6-10 (2003).
4. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch. Gen. Psychiatry 66(8), 848-856 (2009).
5. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin. Psychiatry 59(Suppl. 17), 54-60 (1998).
6. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 14(1 Suppl. 1), 25-31 (2009).
7. Lynch M. Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. 26, 30-36 (2001).
8. Fountoulakis KN, Vieta E, Siamouli M et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann. Gen. Psychiatry 6, 27 (2007).
9. Wittchen H. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety. 16, 162-171 (2002).
10. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617-627 (2005).
11. Schlesser MA, Altshuler KZ. The genetics of affective disorder: data, theory, and clinical applications. Hosp. Community Psychiatry 34(5), 415-422 (1983).
12. Angst J. A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia 2, 381-407 (1961).
13. Pare CM. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. Humangenetik 9(3), 199-201 (1970).
14. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl.) 162(1), 18-23 (2002).
15. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006).
16. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278(1), 441-446 (1996).
17. Gaedigk A, Ndjountche L, Divakaran K et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity. characterization of gene duplication events. Clin. Pharmacol. Ther. 81(2), 242-251 (2007).
18. Bertilsson L, Dahl Ml, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53(2), 111-122 (2002).
19. Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther. Drug Monit. 25(6), 738-742 (2003).
20. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther. Drug Monit. 22(2), 202-208 (2000).
21. Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther. 31(5), 493-502 (2006).
22. Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin. Drug Investig. 31(3), 155-167 (2011).
23. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 28(12), 1095-1128 (1998).
24. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28(12), 1129-1165 (1998).
25. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83(2), 322-327 (2008).
26. Noehr-Jensen L, Zwisler ST, Larsen F et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur. J. Clin. Pharmacol. 65(9), 887-894 (2009).
27. Jin Y, Pollock Bg, Frank E et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J. Clin. Pharmacol. 50(1), 62-72 (2010).
28. Huezo-Diaz P, Perroud N, Spencer E et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J. Psychopharmacol. doi:10.1177/0269881111414451 (2011) (Epub ahead of print).
29. Steimer W, Zopf K, von Amelunxen S et al. Amitriptyline or not, that is the question. pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 51(2), 376-385 (2005).
30. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J. Clin. Psychopharmacol. 17(6), 467-471 (1997).
31. Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11(4), 537-546 (2010).
32. Lobello KW, Preskorn SH, Guico-Pabia CJ et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J. Clin. Psychiatry 71(11), 1482-1487 (2010).
33. Serretti A, Calati R, Massat I et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol. 24(5), 250-256 (2009).
34. Grasmader K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol. 60(5), 329-336 (2004).
35. Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 3(4), e1872 (2008).
36. Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant-treatment response in depression. Neuron 57(2), 203-209 (2008).
37. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22(4), 380-387 (2000).
38. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 54(8), 840-846 (2003).
39. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, Devane CL. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol. Pharm. Bull. 31(2), 231-234 (2008).
40. Ejsing TB, Hasselstrom J, Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol. Drug Interact. 21(3-4), 139-162 (2006).
41. Gex-Fabry M, Eap CB, Oneda B et al. CYP2D6 and ABCB1 genetic variability. influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit. 30(4), 474-482 (2008).
42. Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(2), 398-404 (2008).
43. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol. Res. 58(5-6), 344-347 (2008).
44. Fukui N, Suzuki Y, Sawamura K et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther. Drug Monit. 29(2), 185-189 (2007).
45. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BB, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet. Genomics 20(8), 467-475 (2010).
46. Lin KM, Chiu YF, Tsai IJ et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet. Genomics 21(4), 163-170 (2011).
47. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(6), 1439-1444 (2008).
48. Laika B, Leucht S, Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin. Chem. 52(5), 893-895 (2006).
49. Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 62(3), 193-197 (2010).
50. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant-treatment response in duloxetine-treated patients. Biol. Psychiatry 67(11), 1110-1113 (2010).
51. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 14(12), 1105-1118 (2009).
52. Sakowski SA, Geddes TJ, Thomas DM, Levi E, Hatfield JS, Kuhn DM. Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res. 1085(1), 11-18 (2006).
53. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 11(5), 375-380 (2001).
54. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 6(5), 586-592 (2001).
55. Ham BJ, Lee BC, Paik JW et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(1), 104-107 (2007).
56. Viikki M, Kampman O, Illi A et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci. Lett. 468(1), 80-84 (2010).
57. Ham BJ, Lee MS, Lee HJ et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr. Genet. 15(4), 299-301 (2005).
58. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 6(1), 27-33 (2006).
59. Kato M, Wakeno M, Okugawa G et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 56(4), 167-171 (2007).
60. Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 9(4), 225-233 (2009).
61. Illi A, Setala-Soikkeli E, Viikki M et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20(12), 1125-1128 (2009).
62. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 15(5), 473-500 (2010).
63. Zhang X, Gainetdinov RR, Beaulieu JM et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45(1), 11-16 (2005).
64. Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet. Genomics 18(6), 495-506 (2008).
65. Peters EJ, Slager SL, Mcgrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 9(9), 879-889 (2004).
66. Tsai SJ, Hong CJ, Liou YJ et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant-treatment response. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(4), 637-641 (2009).
67. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103(3), 273-279 (1998).
68. Tzeng DS, Chien CC, Lung FW, Yang CY. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum. Psychopharmacol. 24(4), 293-300 (2009).
69. Domschke K, Hohoff C, Mortensen LS et al. Monoamine oxidase A variant influences antidepressant-treatment response in female patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(1), 224-228 (2008).
70. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 30(9), 1719-1723 (2005).
71. Serretti A, Zanardi R, Franchini L et al. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. Pharmacogenetics 14(9), 607-613 (2004).
72. Muller DJ, Schulze TG, Macciardi F et al. Moclobemide response in depressed patients. association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 35(4), 157-158 (2002).
73. Yoshida K, Naito S, Takahashi H et al. Monoamine oxidase. A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(7-8), 1279-1283 (2002).
74. Yoshida K, Naito S, Takahashi H et al. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 48(1), 10-13 (2003).
75. Leuchter AF, Mccracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J. Clin. Psychopharmacol. 29(4), 372-377 (2009).
76. Tadic A, Muller MJ, Rujescu D et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 144B(3), 325-331 (2007).
77. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry 65(9), 785-791 (2009).
78. Lachman HM, Morrow B, Shprintzen R et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am. J. Med. Genet. 67(5), 468-472 (1996).
79. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl.) 203(1), 155-160 (2009).
80. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158) Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry 25(8), 476-478 (2010).
81. Szegedi A, Rujescu D, Tadic A et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 5(1), 49-53 (2005).
82. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord. 113(1-2), 183-187 (2009).
83. Baune BT, Hohoff C, Berger K et al. Association of the COMT val158met variant with antidepressant-treatment response in major depression. Neuropsychopharmacology 33(4), 924-932 (2008).
84. Yoshida K, Higuchi H, Takahashi H et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol. 23(2), 121-128 (2008).
85. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527-1531 (1996).
86. Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A, Copolov D. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Mol. Med. 4(10), 671-674 (1998).
87. Willeit M, Stastny J, Pirker W et al. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol. Psychiatry 50(1), 8-12 (2001).
88. Shioe K, Ichimiya T, Suhara T et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 48(4), 184-188 (2003).
89. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3(6), 508-511 (1998).
90. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 20(1), 105-107 (2000).
91. Pollock Bg, Ferrell Re, Mulsant Bh et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23(5), 587-590 (2000).
92. Zanardi R, Serretti A, Rossini D et al. Factors affecting fluvoxamine antidepressant activity. influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 50(5), 323-330 (2001).
93. Joyce PR, Mulder RT, Luty SE et al. Age-dependent antidepressant pharmacogenomics. polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 6(4), 339-346 (2003).
94. Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54(9), 879-883 (2003).
95. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol. 23(6), 563-567 (2003).
96. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.) 174(4), 525-529 (2004).
97. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 129B(1), 36-40 (2004).
98. Wilkie MJ, Smith G, Day RK et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 9(1), 61-70 (2009).
99. Mrazek DA, Rush AJ, Biernacka JM et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 150B(3), 341-351 (2009).
100. Huezo-Diaz P, Uher R, Smith R et al. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry 195(1), 30-38 (2009).
101. Smits KM, Smits LJ, Schouten JS, Peeters FP, Prins MH. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin. Ther. 29(4), 691-702 (2007).
102. Kronenberg S, Apter A, Brent D et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J. Child. Adolesc. Psychopharmacol. 17(6), 741-750 (2007).
103. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg Af. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61(11), 1163-1169 (2004).
104. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol. Psychiatry 68(6), 536-543 (2010).
105. Minov C, Baghai TC, Schule C et al. Serotonin-2A-receptor and-transporter polymorphisms. lack of association in patients with major depression. Neurosci. Lett. 303(2), 119-122 (2001).
106. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 7(1), 48-55 (2007).
107. Dogan O, Yuksel N, Ergun MA et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test. 12(2), 225-231 (2008).
108. Kim H, Lim SW, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 296(13), 1609-1618 (2006).
109. Ito K, Yoshida K, Sato K et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 111(2-3), 235-239 (2002).
110. Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry 161(9), 1575-1580 (2004).
111. Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(2), 383-386 (2002).
112. Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11(1), 215-219 (2000).
113. Kang RH, Wong ML, Choi MJ, Paik JW, Lee MS. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(6), 1317-1321 (2007).
114. Keers R, Uher R, Huezo-Diaz P et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J. 11(2), 138-145 (2011).
115. Mandelli L, Mazza M, Martinotti G et al. Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. J. Affect. Disord. 119(1-3), 205-209 (2009).
116. Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783-792 (2007).
117. Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment. Psychopharmacology (Berl.) 178(2-3), 303-308 (2005).
118. Maron E, Tammiste A, Kallassalu K et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol. 19(6), 451-456 (2009).
119. Lee SH, Choi TK, Lee E, Seok JH, Lee HS, Kim SJ. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 62(3), 198-206 (2010).
120. Hougardy DM, Egberts TC, van der Graaf F, Brenninkmeijer VJ, Derijks LJ. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br. J. Clin. Pharmacol. 65(5), 761-766 (2008).
121. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry 58(5), 374-381 (2005).
122. Murthy NV, Selvaraj S, Cowen PJ et al. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 52(1), 50-54 (2010).
123. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry 9(5), 433-441 (2004).
124. Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy-a pilot study. Pharmacogenomics 7(2), 159-166 (2006).
125. Smits K, Smits L, Peeters F et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 22(3), 137-143 (2007).
126. Takahashi H, Yoshida K, Ito K et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur. Neuropsychopharmacol. 12(5), 477-481 (2002).
127. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J. Psychopharmacol. 19(2), 166-172 (2005).
128. Kato M, Fukuda T, Wakeno M et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 150B(1), 115-123 (2009).
129. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31(8), 1745-1749 (2006).
130. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol. 7(4), 453-460 (2004).
131. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol. 7(4), 501-506 (2004).
132. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci. Lett. 436(2), 111-115 (2008).
133. Lin E, Chen PS, Chang HH et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(7), 1167-1172 (2009).
134. Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J. 4(4), 283-286 (2004).
135. Levin GM, Bowles TM, Ehret MJ et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol. Diagn. Ther. 11(3), 155-160 (2007).
136. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur. Neuropsychopharmacol. 16(7), 498-503 (2006).
137. Xu Z, Zhang Z, Shi Y et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J. Psychopharmacol. doi:10.1177/0269881111414452 (2011) (Epub ahead of print).
138. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52(3), 155-162 (2005).
139. Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53(4), 186-195 (2006).
140. Cusin C, Serretti A, Zanardi R et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol. 5(1), 27-35 (2002).
141. Kishi T, Yoshimura R, Kitajima T et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med. 12(3), 237-242 (2010).
142. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 160(10), 1830-1835 (2003).
143. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 31(4), 825-831 (2006).
144. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 31(10), 2281-2288 (2006).
145. Spurlock G, Heils A, Holmans P et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol. Psychiatry 3(1), 42-49 (1998).
146. Mcmahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78(5), 804-814 (2006).
147. Peters EJ, Slager SL, Jenkins GD et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet. Genomics 19(1), 1-10 (2009).
148. Horstmann S, Lucae S, Menke A et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3), 727-740 (2010).
149. Lucae S, Ising M, Horstmann S et al. HTR2A gene variation is involved in antidepressant-treatment response. Eur. Neuropsychopharmacol. 20(1), 65-68 (2010).
150. Noro M, Antonijevic I, Forray C et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 25(4), 228-231 (2010).
151. Tanaka M, Kobayashi D, Murakami Y et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int. J. Neuropsychopharmacol. 11(2), 261-267 (2008).
152. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 6(5), 351-356 (2006).
153. Lee SH, Lee KJ, Lee HJ, Ham BJ, Ryu SH, Lee MS. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin. Neurosci. 59(2), 140-145 (2005).
154. Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44(4), 172-175 (2001).
155. Geracitano R, Federici M, Bernardi G, Mercuri NB. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons. Ann. NY Acad. Sci. 1074, 320-329 (2006).
156. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 1(2), 152-156 (2001).
157. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J. Clin. Psychopharmacol. 26(2), 192-197 (2006).
158. Serretti A, Zanardi R, Cusin C et al. No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res. 104(3), 195-203 (2001).
159. Serretti A, Benedetti F, Colombo C, Lilli R, Lorenzi C, Smeraldi E. Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. Psychiatry Res. 89(2), 107-114 (1999).
160. Garriock HA, Delgado P, Kling MA et al. Number of risk genotypes is a risk factor for major depressive disorder: a case control study. Behav. Brain Funct. 2, 24 (2006).
161. Baffa A, Hohoff C, Baune BT et al. Norepinephrine and serotonin transporter genes. impact on treatment response in depression. Neuropsychobiology 62(2), 121-131 (2010).
162. Zill P, Baghai TC, Engel R et al. Beta-1-adrenergic receptor gene in major depression. influence on antidepressant-treatment response. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 120B(1), 85-89 (2003).
163. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23(5), 477-501 (2000).
164. Liu Z, Zhu F, Wang G et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci. Lett. 414(2), 155-158 (2007).
165. Licinio J, O'Kirwan F, Irizarry K et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant- treatment response in Mexican-Americans. Mol. Psychiatry 9(12), 1075-1082 (2004).
166. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 104(1-3), 83-90 (2007).
167. van Rossum EF, Binder EB, Majer M et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59(8), 681-688 (2006).
168. Brouwer JP, Appelhof BC, van Rossum EF et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 31(10), 1154-1163 (2006).
169. Binder EB, Salyakina D, Lichtner P et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36(12), 1319-1325 (2004).
170. Lekman M, Laje G, Charney D et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry 63(12), 1103-1110 (2008).
171. Kirchheiner J, Lorch R, Lebedeva E et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9(7), 841-846 (2008).
172. Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 144B(8), 1097-1098 (2007).
173. Zou YF, Wang F, Feng XL et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484(1), 56-61 (2010).
174. Horstmann S, Lucae A, Menke A Et al. Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients [poster]. Neuropsychopharmacology 18, S214-S215 (2008).
175. Perroud N, Bondolfi G, Uher R et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 12(3), 365-377 (2011).
176. Brent D, Melhem N, Ferrell R et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 167(2), 190-197 (2010).
177. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J. Clin. Psychiatry 69(6), 946-958 (2008).
178. Nowak G, Li Y, Paul IA. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur. J. Pharmacol. 295(1), 75-85 (1996).
179. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29(1), 23-26 (1996).
180. Paddock S, Laje G, Charney D et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry 164(8), 1181-1188 (2007).
181. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr. Serv. 60(11), 1446-1457 (2009).
182. Laje G, Paddock S, Manji H et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 164(10), 1530-1538 (2007).
183. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, Mcmahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 34(7), 1819-1828 (2009).
184. Rogoz Z, Skuza G, Legutko B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J. Physiol. Pharmacol. 56(4), 661-671 (2005).
185. Rogoz Z, Legutko B. Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol. Rep. 57(6), 840-844 (2005).
186. Rogoz Z, Skuza G, Legutko B. Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J. Physiol. Pharmacol. 58(2), 219-234 (2007).
187. Reagan LP, Hendry RM, Reznikov LR et al. Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala. Eur. J. Pharmacol. 565(1-3), 68-75 (2007).
188. Calabrese F, Molteni R, Maj PF et al. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 32(11), 2351-2359 (2007).
189. Jacobsen JP, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res. 1024(1-2), 183-192 (2004).
190. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269 (2003).
191. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 1118(1), 176-182 (2006).
192. Yoshida K, Higuchi H, Kamata M et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. Psychopharmacol. 21(6), 650-656 (2007).
193. Chi MH, Chang HH, Lee SY et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J. Affect. Disord. 126(3), 430-435 (2010).
194. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 123B(1), 19-22 (2003).
195. Wilkie MJ, Smith D, Reid IC et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics 17(3), 207-215 (2007).
196. Gratacos M, Soria V, Urretavizcaya M et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant-treatment outcome in mood disorders. Pharmacogenomics J. 8(2), 101-112 (2008).
197. Domschke K, Lawford B, Laje G et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant-treatment response. Int. J. Neuropsychopharmacol. 13(1), 93-101 (2010).
198. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant-treatment response. Arch. Gen. Psychiatry 66(5), 488-497 (2009).
199. Perroud N, Aitchison KJ, Uher R et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34(12), 2517-2528 (2009).
200. Siffert W, Rosskopf D, Siffert G et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18(1), 45-48 (1998).
201. Zill P, Baghai TC, Zwanzger P et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 11(9), 1893-1897 (2000).
202. Serretti A, Lorenzi C, Cusin C et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur. Neuropsychopharmacol. 13(2), 117-122 (2003).
203. Lee HJ, Cha JH, Ham BJ et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 4(1), 29-33 (2004).
204. Keers R, Bonvicini C, Scassellati C et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. J. Psychopharmacol. 25(7), 867-874 (2011).
205. Kang RH, Hahn SW, Choi MJ, Lee MS. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 56(1), 1-5 (2007).
206. Kato M, Wakeno M, Okugawa G et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(4), 1041-1044 (2008).
207. Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383), 1640-1645 (1998).
208. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
209. Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol. Psychiatry 40(11), 1122-1127 (1996).
210. Baghai TC, Schule C, Zwanzger P et al. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol. Psychiatry 6(3), 258-259 (2001).
211. Baghai TC, Schule C, Zill P et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci. Lett. 363(1), 38-42 (2004).
212. Bondy B, Baghai TC, Zill P et al. Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 1094-1099 (2005).
213. Dowlatshahi D, Macqueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352(9142), 1754-1755 (1998).
214. Perlis RH, Purcell S, Fava M et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch. Gen. Psychiatry 64(6), 689-697 (2007).
215. Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66(9), 966-975 (2009).
216. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167(5), 555-564 (2010).
217. Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67(2), 133-138 (2010).
218. Hettema JM. What is the genetic relationship between anxiety and depression? Am. J. Med. Genet. C Semin. Med. Genet. 148C(2), 140-146 (2008).
219. Bespalov AY, van Gaalen MM, Gross G. Antidepressant treatment in anxiety disorders. Curr. Top. Behav. Neurosci. 2, 361-390 (2010).
220. Tiwari AK, Souza RP, Muller DJ. Pharmacogenetics of anxiolytic drugs. J. Neural. Transm. 116(6), 667-677 (2009).
221. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg Hg. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J. Clin. Psychiatry 68(5), 747-753 (2007).
222. Mcdougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol. Psychiatry 3(3), 270-273 (1998).
223. Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol. Psychiatry 2(5), 403-406 (1997).
224. Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J. 2(3), 176-181 (2002).
225. Zhang L, Liu X, Li T, Yang Y, Hu X, Collier D. [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(5), 479-481 (2004).
226. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30(12), 2230-2235 (2005).
227. Kim W, Choi YH, Yoon KS, Cho DY, Pae CU, Woo JM. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(8), 1413-1418 (2006).
228. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl.) 187(1), 68-72 (2006).
229. Lenze EJ, Goate AM, Nowotny P et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J. Clin. Psychopharmacol. 30(6), 672-677 (2010).
230. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O. T102C and-1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur. Psychiatry 18(5), 249-254 (2003).
231. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. doi: 10.1038/tpj.2011.47 (2011) (Epub ahead of print).
232. Lawford BR, Mc DYR, Noble EP et al. D2 dopamine receptor gene polymorphism. paroxetine and social functioning in posttraumatic stress disorder. Eur. Neuropsychopharmacol. 13(5), 313-320 (2003).
233. Domschke K, Dannlowski U, Ohrmann P et al. Cannabinoid receptor 1 (CNR1) gene. impact on antidepressant-treatment response and emotion processing in major depression. Eur. Neuropsychopharmacol. 18(10), 751-759 (2008).
234. Narasimhan S, Aquino TD, Hodge R, Rickels K, Lohoff FW. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci. Lett. 503(3), 200-202 (2011).
235. Gould TD, Manji HK. Signaling networks in the pathophysiology and treatment of mood disorders. J. Psychosom. Res. 53(2), 687-697 (2002).
236. Lin CN, Tsai SJ, Hong CJ. Association analysis of a functional G protein beta3 subunit gene polymorphism (C825T) in mood disorders. Neuropsychobiology 44(3), 118-121 (2001).
237. Kunugi H, Kato T, Fukuda R, Tatsumi M, Sakai T, Nanko S. Association study of C825T polymorphism of the G-protein b3 subunit gene with schizophrenia and mood disorders. J. Neural. Transm. 109(2), 213-218 (2002).
238. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 5(6), 407-420 (2003).
239. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch. Gen. Psychiatry 58(6), 539-544 (2001).
240. Masoliver E, Menoyo A, Perez V et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr. Genet. 16(1), 25-29 (2006).
241. Ferreira AA, Neves FS, Da Rocha FF et al. The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J. Affect. Disord. 112(1-3), 267-272 (2009).
242. Rousseva A, Henry C, van den Bulke D et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 3(2), 101-104 (2003).
243. Serretti A, Artioli P, Zanardi R et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl.) 174(4), 504-511 (2004).
244. Baumer FM, Howe M, Gallelli K, Simeonova DI, Hallmayer J, Chang KD. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol. Psychiatry 60(9), 1005-1012 (2006).
245. Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord. 12(7), 702-706 (2010).
246. Zai G, Mundo E, Strauss J, Wong GW, Kennedy JL. Brain-derived neurotrophic factor (BDNF) gene not associated with antidepressant-induced mania. Bipolar Disord. 9(5), 521-525 (2007).
247. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).